pp-194 Solution for infusion

Indication: Pancreatic ductal adenocarcinoma (PDAC) — Phase 2b planned in combination with chemotherapy Clinical stage: Phase 2b — planned H2 2025 (following positive Phase 2a signal) Modality: Biological (first-in-class anti-CEACAM1 monoclonal antibody) Mechanism / Target: First-in-class antibody targeting CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1); dual mechanism: (1) blocks CEACAM1-mediated T-cell immune checkpoint restoring cytotoxic T-cell activity; (2) disrupts CEACAM1–EGF receptor oncogenic interaction promoting tumour survival Route / form: IV infusion Differentiation: First-in-class anti-CEACAM1 immunotherapy; dual immune checkpoint and tumour survival blocking mechanism; addresses PDAC — a tumour type resistant to current immunotherapy; Phase 2b planned in pancreatic cancer where no approved immunotherapy exists;